| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 33 | 2024 | 701 | 3.090 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 21 | 2024 | 114 | 2.830 |
Why?
|
| Neoplasms | 32 | 2023 | 2697 | 2.570 |
Why?
|
| Mutation | 64 | 2024 | 5773 | 2.560 |
Why?
|
| Genomics | 25 | 2024 | 1467 | 2.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 29 | 2024 | 1881 | 1.700 |
Why?
|
| Neuroblastoma | 16 | 2024 | 501 | 1.660 |
Why?
|
| Genome, Human | 22 | 2022 | 1255 | 1.660 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 18 | 2024 | 1242 | 1.270 |
Why?
|
| Genetic Predisposition to Disease | 23 | 2022 | 2997 | 1.260 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 9 | 2017 | 31 | 1.150 |
Why?
|
| Biomarkers, Tumor | 14 | 2021 | 1414 | 1.100 |
Why?
|
| DNA Methylation | 23 | 2022 | 971 | 1.060 |
Why?
|
| Humans | 219 | 2024 | 121793 | 1.060 |
Why?
|
| Oncogene Proteins, Fusion | 11 | 2021 | 194 | 1.040 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2023 | 87 | 1.030 |
Why?
|
| Transcriptome | 16 | 2021 | 906 | 1.000 |
Why?
|
| Comparative Genomic Hybridization | 8 | 2013 | 576 | 0.980 |
Why?
|
| Wilms Tumor | 8 | 2019 | 112 | 0.960 |
Why?
|
| Kidney Neoplasms | 10 | 2019 | 424 | 0.950 |
Why?
|
| DNA Copy Number Variations | 20 | 2022 | 941 | 0.950 |
Why?
|
| Child | 94 | 2024 | 23789 | 0.940 |
Why?
|
| Gene Amplification | 8 | 2021 | 228 | 0.910 |
Why?
|
| Polymorphism, Single Nucleotide | 27 | 2022 | 2511 | 0.870 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 15 | 2015 | 999 | 0.840 |
Why?
|
| Female | 122 | 2024 | 64573 | 0.830 |
Why?
|
| Prognosis | 34 | 2024 | 4438 | 0.790 |
Why?
|
| Osteosarcoma | 8 | 2022 | 255 | 0.780 |
Why?
|
| Male | 107 | 2024 | 59243 | 0.760 |
Why?
|
| Thyroid Neoplasms | 3 | 2024 | 190 | 0.760 |
Why?
|
| N-Myc Proto-Oncogene Protein | 10 | 2021 | 55 | 0.750 |
Why?
|
| Child, Preschool | 57 | 2024 | 13661 | 0.730 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2012 | 92 | 0.730 |
Why?
|
| Disease-Free Survival | 23 | 2024 | 860 | 0.720 |
Why?
|
| Chromosome Deletion | 8 | 2018 | 636 | 0.710 |
Why?
|
| Dandy-Walker Syndrome | 1 | 2020 | 11 | 0.700 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2018 | 638 | 0.690 |
Why?
|
| Oncogene Proteins | 8 | 2018 | 138 | 0.680 |
Why?
|
| Pancreatic Cyst | 1 | 2020 | 30 | 0.680 |
Why?
|
| Antineoplastic Agents | 7 | 2022 | 1672 | 0.670 |
Why?
|
| Carcinogenesis | 4 | 2018 | 335 | 0.670 |
Why?
|
| Infant | 50 | 2024 | 12177 | 0.670 |
Why?
|
| GATA3 Transcription Factor | 6 | 2022 | 37 | 0.670 |
Why?
|
| Genome-Wide Association Study | 13 | 2021 | 1587 | 0.660 |
Why?
|
| Adolescent | 54 | 2024 | 18773 | 0.650 |
Why?
|
| Genes, Neoplasm | 5 | 2018 | 79 | 0.640 |
Why?
|
| Abnormalities, Multiple | 5 | 2020 | 967 | 0.640 |
Why?
|
| Germ-Line Mutation | 8 | 2021 | 303 | 0.630 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2019 | 715 | 0.630 |
Why?
|
| Neoplasm, Residual | 11 | 2023 | 116 | 0.630 |
Why?
|
| Nervous System Malformations | 1 | 2020 | 125 | 0.610 |
Why?
|
| Pleural Neoplasms | 1 | 2018 | 42 | 0.610 |
Why?
|
| Genetic Variation | 10 | 2022 | 1460 | 0.610 |
Why?
|
| Oncogene Fusion | 1 | 2018 | 22 | 0.610 |
Why?
|
| Nuclear Proteins | 13 | 2018 | 1280 | 0.600 |
Why?
|
| Mesothelioma | 1 | 2018 | 54 | 0.600 |
Why?
|
| Gene Expression Profiling | 13 | 2024 | 1675 | 0.600 |
Why?
|
| Mutation Rate | 4 | 2018 | 66 | 0.590 |
Why?
|
| Adenocarcinoma | 4 | 2018 | 997 | 0.590 |
Why?
|
| Cell Cycle Proteins | 3 | 2020 | 657 | 0.590 |
Why?
|
| Bone Neoplasms | 7 | 2022 | 422 | 0.580 |
Why?
|
| Methotrexate | 9 | 2020 | 325 | 0.580 |
Why?
|
| Gene Fusion | 6 | 2017 | 55 | 0.580 |
Why?
|
| Databases, Genetic | 11 | 2018 | 467 | 0.570 |
Why?
|
| Ubiquitination | 1 | 2018 | 173 | 0.570 |
Why?
|
| Young Adult | 32 | 2024 | 8676 | 0.560 |
Why?
|
| In Situ Hybridization, Fluorescence | 15 | 2016 | 759 | 0.560 |
Why?
|
| Paired Box Transcription Factors | 9 | 2016 | 75 | 0.550 |
Why?
|
| Signal Transduction | 18 | 2022 | 4518 | 0.540 |
Why?
|
| Burkitt Lymphoma | 3 | 2024 | 146 | 0.540 |
Why?
|
| Cerebellum | 1 | 2020 | 410 | 0.530 |
Why?
|
| Cell Line, Tumor | 17 | 2020 | 3297 | 0.530 |
Why?
|
| Molecular Targeted Therapy | 5 | 2020 | 353 | 0.530 |
Why?
|
| Philadelphia Chromosome | 6 | 2023 | 39 | 0.520 |
Why?
|
| MicroRNAs | 15 | 2024 | 836 | 0.510 |
Why?
|
| Adult | 50 | 2024 | 28549 | 0.510 |
Why?
|
| Down Syndrome | 3 | 2023 | 183 | 0.500 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2018 | 342 | 0.500 |
Why?
|
| Metabolic Networks and Pathways | 5 | 2018 | 179 | 0.490 |
Why?
|
| Aneuploidy | 6 | 2018 | 156 | 0.490 |
Why?
|
| Sarcoma | 3 | 2020 | 192 | 0.490 |
Why?
|
| Lung Neoplasms | 4 | 2018 | 1582 | 0.480 |
Why?
|
| Gene Deletion | 4 | 2018 | 798 | 0.470 |
Why?
|
| Translocation, Genetic | 6 | 2021 | 352 | 0.460 |
Why?
|
| Chromosomes, Human, Pair 2 | 4 | 2011 | 118 | 0.450 |
Why?
|
| HMGA2 Protein | 2 | 2014 | 8 | 0.450 |
Why?
|
| Head and Neck Neoplasms | 2 | 2015 | 465 | 0.450 |
Why?
|
| Chromosomes, Human, X | 2 | 2018 | 156 | 0.440 |
Why?
|
| Gene Dosage | 6 | 2017 | 441 | 0.440 |
Why?
|
| Genetic Heterogeneity | 2 | 2020 | 123 | 0.440 |
Why?
|
| Genetic Testing | 5 | 2022 | 988 | 0.430 |
Why?
|
| Chernobyl Nuclear Accident | 2 | 2024 | 5 | 0.430 |
Why?
|
| Mosaicism | 3 | 2019 | 241 | 0.430 |
Why?
|
| Breast Neoplasms | 6 | 2018 | 2478 | 0.420 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2022 | 714 | 0.420 |
Why?
|
| ras Proteins | 4 | 2018 | 135 | 0.420 |
Why?
|
| Exome | 10 | 2022 | 1034 | 0.410 |
Why?
|
| Epigenesis, Genetic | 11 | 2022 | 659 | 0.410 |
Why?
|
| PAX7 Transcription Factor | 7 | 2014 | 17 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2018 | 187 | 0.410 |
Why?
|
| Clonal Evolution | 3 | 2018 | 38 | 0.410 |
Why?
|
| Neoplasm Proteins | 6 | 2020 | 669 | 0.400 |
Why?
|
| Uniparental Disomy | 2 | 2011 | 49 | 0.400 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 992 | 0.400 |
Why?
|
| Carcinoma | 1 | 2014 | 279 | 0.400 |
Why?
|
| Chromosome Mapping | 10 | 2009 | 1064 | 0.400 |
Why?
|
| Melanoma | 2 | 2017 | 834 | 0.390 |
Why?
|
| Dwarfism | 1 | 2012 | 102 | 0.390 |
Why?
|
| Repressor Proteins | 5 | 2021 | 813 | 0.380 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 4 | 2013 | 23 | 0.380 |
Why?
|
| Transcription Factors | 11 | 2018 | 2580 | 0.380 |
Why?
|
| Rectal Neoplasms | 1 | 2012 | 76 | 0.370 |
Why?
|
| Gene Regulatory Networks | 4 | 2020 | 352 | 0.370 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2020 | 217 | 0.370 |
Why?
|
| Sequence Analysis, DNA | 10 | 2018 | 1759 | 0.370 |
Why?
|
| Sequence Analysis, RNA | 6 | 2021 | 374 | 0.370 |
Why?
|
| Survival Rate | 13 | 2024 | 1976 | 0.360 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2021 | 1189 | 0.360 |
Why?
|
| Dystrophin | 1 | 2010 | 37 | 0.360 |
Why?
|
| Proteome | 2 | 2017 | 231 | 0.360 |
Why?
|
| Homozygote | 5 | 2020 | 533 | 0.360 |
Why?
|
| DNA Polymerase II | 2 | 2018 | 19 | 0.360 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 2 | 2018 | 29 | 0.350 |
Why?
|
| Pedigree | 8 | 2020 | 1574 | 0.350 |
Why?
|
| Recurrence | 11 | 2024 | 1408 | 0.350 |
Why?
|
| Alleles | 8 | 2021 | 1585 | 0.350 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2015 | 542 | 0.340 |
Why?
|
| RNA, Long Noncoding | 4 | 2018 | 209 | 0.340 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 254 | 0.340 |
Why?
|
| RNA Splicing Factors | 2 | 2018 | 49 | 0.330 |
Why?
|
| Chromatin | 4 | 2022 | 550 | 0.330 |
Why?
|
| Gene Frequency | 8 | 2018 | 701 | 0.330 |
Why?
|
| Neoplasm Staging | 12 | 2024 | 1206 | 0.330 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2009 | 59 | 0.320 |
Why?
|
| X Chromosome Inactivation | 1 | 2009 | 63 | 0.320 |
Why?
|
| Infant, Newborn | 15 | 2024 | 8009 | 0.320 |
Why?
|
| Receptors, Cytokine | 5 | 2022 | 57 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1103 | 0.310 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2022 | 297 | 0.310 |
Why?
|
| Cluster Analysis | 7 | 2020 | 384 | 0.310 |
Why?
|
| Testicular Neoplasms | 3 | 2018 | 137 | 0.310 |
Why?
|
| Genetic Loci | 4 | 2014 | 332 | 0.310 |
Why?
|
| Stomach Neoplasms | 1 | 2014 | 537 | 0.310 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2018 | 54 | 0.310 |
Why?
|
| Oncogenes | 5 | 2022 | 171 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-ets | 2 | 2021 | 56 | 0.300 |
Why?
|
| Phenotype | 16 | 2020 | 4200 | 0.300 |
Why?
|
| Asparaginase | 6 | 2020 | 39 | 0.300 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 284 | 0.300 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 800 | 0.300 |
Why?
|
| Chromosomal Instability | 1 | 2018 | 58 | 0.300 |
Why?
|
| Developmental Disabilities | 4 | 2020 | 693 | 0.290 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2021 | 864 | 0.290 |
Why?
|
| RNA, Neoplasm | 4 | 2017 | 138 | 0.290 |
Why?
|
| Carcinosarcoma | 1 | 2017 | 10 | 0.290 |
Why?
|
| Base Sequence | 15 | 2018 | 3117 | 0.280 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2018 | 80 | 0.280 |
Why?
|
| Machine Learning | 3 | 2018 | 213 | 0.280 |
Why?
|
| Transforming Growth Factor beta | 3 | 2018 | 460 | 0.280 |
Why?
|
| Papillomaviridae | 2 | 2020 | 124 | 0.280 |
Why?
|
| Iodine Radioisotopes | 2 | 2024 | 75 | 0.280 |
Why?
|
| Germ Cells | 2 | 2018 | 185 | 0.270 |
Why?
|
| Polyethylene Glycols | 6 | 2020 | 215 | 0.270 |
Why?
|
| Genes, myc | 2 | 2018 | 99 | 0.270 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1513 | 0.270 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 4 | 2016 | 46 | 0.270 |
Why?
|
| Alternative Splicing | 2 | 2018 | 346 | 0.270 |
Why?
|
| Chromosome Aberrations | 6 | 2023 | 614 | 0.270 |
Why?
|
| Muscular Dystrophy, Duchenne | 3 | 2012 | 63 | 0.270 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2019 | 173 | 0.270 |
Why?
|
| DNA, Neoplasm | 3 | 2015 | 301 | 0.260 |
Why?
|
| Forkhead Transcription Factors | 7 | 2015 | 371 | 0.260 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 117 | 0.260 |
Why?
|
| Growth Disorders | 2 | 2013 | 208 | 0.250 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 154 | 0.250 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2018 | 465 | 0.250 |
Why?
|
| Genotype | 12 | 2021 | 2483 | 0.250 |
Why?
|
| Middle Aged | 18 | 2024 | 25516 | 0.250 |
Why?
|
| Pathology, Molecular | 2 | 2022 | 60 | 0.250 |
Why?
|
| DNA-Binding Proteins | 8 | 2018 | 2032 | 0.240 |
Why?
|
| RNA, Messenger | 6 | 2018 | 2829 | 0.240 |
Why?
|
| Sequence Deletion | 2 | 2013 | 528 | 0.240 |
Why?
|
| Algorithms | 6 | 2019 | 1569 | 0.240 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2024 | 81 | 0.240 |
Why?
|
| Pathologists | 2 | 2022 | 29 | 0.240 |
Why?
|
| Carcinoma, Papillary | 2 | 2015 | 76 | 0.240 |
Why?
|
| 5'-Nucleotidase | 3 | 2022 | 16 | 0.230 |
Why?
|
| DNA Mutational Analysis | 6 | 2015 | 793 | 0.230 |
Why?
|
| Ganglioneuroma | 2 | 2017 | 17 | 0.230 |
Why?
|
| Intellectual Disability | 4 | 2019 | 1038 | 0.230 |
Why?
|
| Syndrome | 8 | 2013 | 1110 | 0.230 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2024 | 160 | 0.230 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2018 | 53 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 4 | 3 | 2013 | 58 | 0.230 |
Why?
|
| Microcephaly | 2 | 2020 | 327 | 0.230 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2018 | 235 | 0.230 |
Why?
|
| Protein Kinases | 2 | 2017 | 330 | 0.220 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2021 | 33 | 0.220 |
Why?
|
| Medical Oncology | 4 | 2020 | 208 | 0.220 |
Why?
|
| Aged | 13 | 2021 | 18732 | 0.220 |
Why?
|
| Loss of Heterozygosity | 6 | 2021 | 125 | 0.220 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 184 | 0.220 |
Why?
|
| Genes, p53 | 2 | 2015 | 215 | 0.220 |
Why?
|
| Dexamethasone | 4 | 2019 | 274 | 0.220 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 137 | 0.220 |
Why?
|
| Virus Integration | 3 | 2017 | 41 | 0.210 |
Why?
|
| Lymphatic Metastasis | 1 | 2024 | 396 | 0.210 |
Why?
|
| Forkhead Box Protein O1 | 6 | 2015 | 94 | 0.210 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2021 | 27 | 0.210 |
Why?
|
| Exons | 6 | 2013 | 793 | 0.210 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 6275 | 0.210 |
Why?
|
| Mutation, Missense | 4 | 2020 | 840 | 0.210 |
Why?
|
| Proportional Hazards Models | 7 | 2018 | 1269 | 0.200 |
Why?
|
| Induction Chemotherapy | 5 | 2021 | 42 | 0.200 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2018 | 156 | 0.200 |
Why?
|
| Bronchopulmonary Dysplasia | 2 | 2016 | 184 | 0.200 |
Why?
|
| Up-Regulation | 3 | 2022 | 872 | 0.200 |
Why?
|
| Treatment Outcome | 16 | 2023 | 12003 | 0.200 |
Why?
|
| Chromosomes, Human | 7 | 2019 | 130 | 0.200 |
Why?
|
| Endometrial Neoplasms | 1 | 2013 | 99 | 0.200 |
Why?
|
| Molecular Sequence Data | 10 | 2016 | 3886 | 0.200 |
Why?
|
| Accreditation | 2 | 2022 | 82 | 0.200 |
Why?
|
| Neoplasm Metastasis | 4 | 2018 | 653 | 0.190 |
Why?
|
| Genetic Association Studies | 5 | 2020 | 744 | 0.190 |
Why?
|
| CpG Islands | 6 | 2018 | 313 | 0.190 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2022 | 137 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 879 | 0.190 |
Why?
|
| Child Development Disorders, Pervasive | 2 | 2013 | 82 | 0.190 |
Why?
|
| Genes, rel | 1 | 2001 | 1 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2019 | 139 | 0.190 |
Why?
|
| Risk Factors | 14 | 2023 | 9718 | 0.190 |
Why?
|
| Ikaros Transcription Factor | 4 | 2015 | 25 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 688 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2018 | 97 | 0.190 |
Why?
|
| Immunohistochemistry | 5 | 2021 | 1710 | 0.190 |
Why?
|
| Glioma | 2 | 2016 | 467 | 0.190 |
Why?
|
| Karyotyping | 3 | 2019 | 338 | 0.190 |
Why?
|
| Recombination, Genetic | 2 | 2010 | 446 | 0.190 |
Why?
|
| Receptors, Somatotropin | 1 | 2000 | 9 | 0.180 |
Why?
|
| Polymorphism, Genetic | 4 | 2018 | 800 | 0.180 |
Why?
|
| SOX9 Transcription Factor | 2 | 2018 | 83 | 0.180 |
Why?
|
| Survival Analysis | 7 | 2020 | 1463 | 0.180 |
Why?
|
| Genome | 1 | 2013 | 471 | 0.180 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 3 | 1997 | 368 | 0.180 |
Why?
|
| Genes, ras | 2 | 2021 | 96 | 0.180 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2020 | 10 | 0.180 |
Why?
|
| Trisomy | 1 | 2021 | 104 | 0.180 |
Why?
|
| DNA | 5 | 2022 | 1606 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 320 | 0.180 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 428 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 6 | 2020 | 1351 | 0.180 |
Why?
|
| Cohort Studies | 10 | 2020 | 4623 | 0.180 |
Why?
|
| Precision Medicine | 2 | 2021 | 306 | 0.180 |
Why?
|
| Hypertension, Pulmonary | 2 | 2016 | 428 | 0.170 |
Why?
|
| Case-Control Studies | 9 | 2019 | 3132 | 0.170 |
Why?
|
| Gene Rearrangement | 4 | 2019 | 323 | 0.170 |
Why?
|
| Rhabdomyosarcoma | 3 | 2019 | 170 | 0.170 |
Why?
|
| RNA-Binding Proteins | 3 | 2018 | 569 | 0.170 |
Why?
|
| AMP Deaminase | 1 | 2019 | 4 | 0.170 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 6 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2014 | 371 | 0.170 |
Why?
|
| Collagen Type XI | 1 | 2019 | 4 | 0.170 |
Why?
|
| Biological Evolution | 1 | 2001 | 221 | 0.170 |
Why?
|
| Flow Cytometry | 3 | 2018 | 808 | 0.170 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2019 | 17 | 0.170 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2018 | 153 | 0.170 |
Why?
|
| B7-H1 Antigen | 3 | 2018 | 99 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 225 | 0.170 |
Why?
|
| Vitreous Detachment | 1 | 2019 | 15 | 0.170 |
Why?
|
| Connective Tissue Diseases | 1 | 2019 | 29 | 0.170 |
Why?
|
| Herpesvirus 4, Human | 3 | 2023 | 662 | 0.170 |
Why?
|
| Microsatellite Repeats | 3 | 2013 | 218 | 0.170 |
Why?
|
| Telomerase | 3 | 2016 | 164 | 0.170 |
Why?
|
| Diploidy | 1 | 2019 | 36 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2018 | 28 | 0.170 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 42 | 0.170 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2019 | 15 | 0.160 |
Why?
|
| Proteomics | 3 | 2018 | 475 | 0.160 |
Why?
|
| Daunorubicin | 1 | 2019 | 27 | 0.160 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 269 | 0.160 |
Why?
|
| PAX5 Transcription Factor | 1 | 2019 | 13 | 0.160 |
Why?
|
| Ploidies | 1 | 2019 | 37 | 0.160 |
Why?
|
| Cerebellar Diseases | 1 | 2019 | 74 | 0.160 |
Why?
|
| Genetics, Medical | 1 | 2020 | 117 | 0.160 |
Why?
|
| Genes, Immunoglobulin | 1 | 2019 | 33 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2021 | 629 | 0.160 |
Why?
|
| Protein Methyltransferases | 1 | 2018 | 9 | 0.160 |
Why?
|
| PAX3 Transcription Factor | 4 | 2013 | 27 | 0.160 |
Why?
|
| Trinucleotide Repeats | 2 | 1996 | 109 | 0.160 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2019 | 93 | 0.160 |
Why?
|
| Cell Self Renewal | 1 | 2018 | 41 | 0.160 |
Why?
|
| Thyroid Gland | 2 | 2021 | 117 | 0.160 |
Why?
|
| Adenosine Monophosphate | 1 | 2018 | 43 | 0.160 |
Why?
|
| Cell Cycle | 3 | 2018 | 619 | 0.160 |
Why?
|
| Gene Duplication | 2 | 2018 | 358 | 0.160 |
Why?
|
| Th1-Th2 Balance | 1 | 2018 | 8 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 959 | 0.150 |
Why?
|
| Epilepsy | 2 | 2019 | 856 | 0.150 |
Why?
|
| Transcription Factors, TFII | 1 | 2018 | 7 | 0.150 |
Why?
|
| Microsatellite Instability | 3 | 2018 | 36 | 0.150 |
Why?
|
| Cell Dedifferentiation | 1 | 2018 | 21 | 0.150 |
Why?
|
| Recombinational DNA Repair | 1 | 2018 | 19 | 0.150 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2020 | 214 | 0.150 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 129 | 0.150 |
Why?
|
| Ganglioglioma | 1 | 2018 | 24 | 0.150 |
Why?
|
| Thymoma | 1 | 2018 | 11 | 0.150 |
Why?
|
| Interleukin-33 | 1 | 2017 | 14 | 0.150 |
Why?
|
| Leucovorin | 4 | 2020 | 50 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 2 | 2015 | 1113 | 0.150 |
Why?
|
| United States | 9 | 2022 | 10413 | 0.150 |
Why?
|
| RNA Splice Sites | 1 | 2018 | 87 | 0.150 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 29 | 0.150 |
Why?
|
| Proteins | 4 | 2013 | 1039 | 0.150 |
Why?
|
| Janus Kinases | 2 | 2022 | 31 | 0.150 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2018 | 36 | 0.150 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 45 | 0.150 |
Why?
|
| HEK293 Cells | 5 | 2018 | 742 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2014 | 140 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 105 | 0.150 |
Why?
|
| Biological Specimen Banks | 1 | 2018 | 51 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2018 | 87 | 0.150 |
Why?
|
| Age Factors | 6 | 2021 | 2757 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2024 | 547 | 0.140 |
Why?
|
| Follow-Up Studies | 7 | 2024 | 4953 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 167 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2017 | 138 | 0.140 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2018 | 538 | 0.140 |
Why?
|
| Paraganglioma | 1 | 2017 | 19 | 0.140 |
Why?
|
| Myogenin | 2 | 2014 | 11 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2017 | 139 | 0.140 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 33 | 0.140 |
Why?
|
| Uveal Neoplasms | 1 | 2017 | 54 | 0.140 |
Why?
|
| Animals | 20 | 2023 | 33870 | 0.140 |
Why?
|
| Anaplasia | 1 | 2016 | 6 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2020 | 258 | 0.140 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 316 | 0.140 |
Why?
|
| Membrane Proteins | 3 | 2015 | 1520 | 0.140 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 390 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 1380 | 0.140 |
Why?
|
| Radius | 1 | 2016 | 25 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2018 | 379 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 216 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 295 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 278 | 0.130 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 535 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-ret | 3 | 2024 | 29 | 0.130 |
Why?
|
| Receptors, Erythropoietin | 1 | 2016 | 12 | 0.130 |
Why?
|
| Gene Order | 1 | 2016 | 78 | 0.130 |
Why?
|
| Amidohydrolases | 1 | 2016 | 18 | 0.130 |
Why?
|
| DNA Repair | 2 | 2018 | 580 | 0.130 |
Why?
|
| Mercaptopurine | 3 | 2022 | 71 | 0.130 |
Why?
|
| Quality Control | 2 | 2018 | 116 | 0.130 |
Why?
|
| Retinoblastoma Protein | 2 | 2013 | 76 | 0.130 |
Why?
|
| Carcinoma, Lobular | 1 | 2015 | 24 | 0.130 |
Why?
|
| Interferon-gamma | 1 | 2018 | 511 | 0.130 |
Why?
|
| Mice | 15 | 2023 | 17624 | 0.130 |
Why?
|
| VDJ Exons | 1 | 2015 | 1 | 0.130 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 20 | 0.120 |
Why?
|
| Chromosomes, Artificial, Bacterial | 3 | 2010 | 93 | 0.120 |
Why?
|
| NFI Transcription Factors | 1 | 2015 | 50 | 0.120 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 49 | 0.120 |
Why?
|
| Protein Array Analysis | 2 | 2012 | 101 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2015 | 59 | 0.120 |
Why?
|
| Amino Acid Sequence | 6 | 2016 | 2700 | 0.120 |
Why?
|
| Mitotic Index | 1 | 2014 | 19 | 0.120 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2014 | 12 | 0.120 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 105 | 0.120 |
Why?
|
| Ovarian Neoplasms | 2 | 2013 | 412 | 0.120 |
Why?
|
| Odds Ratio | 4 | 2021 | 1189 | 0.120 |
Why?
|
| Campomelic Dysplasia | 1 | 2014 | 5 | 0.120 |
Why?
|
| Ribonuclease III | 1 | 2015 | 87 | 0.120 |
Why?
|
| Arginase | 1 | 2014 | 28 | 0.120 |
Why?
|
| Sarcoglycans | 2 | 2011 | 7 | 0.120 |
Why?
|
| Wound Healing | 1 | 2018 | 454 | 0.120 |
Why?
|
| Quantitative Trait Loci | 3 | 2018 | 263 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2015 | 207 | 0.120 |
Why?
|
| Macrophages | 1 | 2018 | 612 | 0.110 |
Why?
|
| Cell Proliferation | 6 | 2018 | 2321 | 0.110 |
Why?
|
| Biopsy | 5 | 2020 | 1253 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2014 | 119 | 0.110 |
Why?
|
| Karyotype | 1 | 2013 | 29 | 0.110 |
Why?
|
| Mitosis | 1 | 2014 | 239 | 0.110 |
Why?
|
| Amelogenin | 1 | 2013 | 3 | 0.110 |
Why?
|
| Urogenital Neoplasms | 1 | 2013 | 16 | 0.110 |
Why?
|
| Chromosomes | 2 | 2019 | 199 | 0.110 |
Why?
|
| Tacrolimus | 1 | 2014 | 99 | 0.110 |
Why?
|
| Risk | 4 | 2021 | 724 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 319 | 0.110 |
Why?
|
| Cell Nucleolus | 1 | 2013 | 56 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2013 | 40 | 0.110 |
Why?
|
| Receptors, Estrogen | 2 | 2018 | 788 | 0.110 |
Why?
|
| Receptors, GABA-A | 1 | 2013 | 58 | 0.110 |
Why?
|
| Age of Onset | 2 | 2015 | 578 | 0.110 |
Why?
|
| Graft vs Host Disease | 2 | 2015 | 542 | 0.110 |
Why?
|
| Vincristine | 3 | 2019 | 206 | 0.110 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2013 | 31 | 0.110 |
Why?
|
| Prednisone | 3 | 2020 | 272 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1244 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2018 | 204 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2012 | 13 | 0.100 |
Why?
|
| Retrospective Studies | 10 | 2021 | 15794 | 0.100 |
Why?
|
| Genes, erbB-2 | 1 | 2012 | 37 | 0.100 |
Why?
|
| Prader-Willi Syndrome | 1 | 2013 | 66 | 0.100 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2012 | 31 | 0.100 |
Why?
|
| Receptors, Androgen | 1 | 2015 | 408 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2013 | 159 | 0.100 |
Why?
|
| Genes, BRCA1 | 1 | 2012 | 51 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2011 | 50 | 0.100 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 252 | 0.100 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 74 | 0.100 |
Why?
|
| Chromosome Breakage | 2 | 2010 | 168 | 0.100 |
Why?
|
| Sirolimus | 1 | 2014 | 220 | 0.100 |
Why?
|
| Genetic Counseling | 2 | 2011 | 219 | 0.100 |
Why?
|
| DNA, Complementary | 3 | 2009 | 465 | 0.100 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2017 | 71 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2018 | 217 | 0.100 |
Why?
|
| Pelvic Neoplasms | 1 | 2012 | 21 | 0.100 |
Why?
|
| STAT5 Transcription Factor | 1 | 2012 | 89 | 0.100 |
Why?
|
| Sarcoma, Ewing | 2 | 2019 | 109 | 0.100 |
Why?
|
| Cell Differentiation | 3 | 2015 | 1933 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 1300 | 0.100 |
Why?
|
| Computational Biology | 4 | 2018 | 790 | 0.100 |
Why?
|
| Introns | 3 | 2001 | 301 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2014 | 701 | 0.090 |
Why?
|
| Contactins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Epigenomics | 2 | 2017 | 160 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2018 | 269 | 0.090 |
Why?
|
| Genetic Markers | 4 | 2017 | 590 | 0.090 |
Why?
|
| Gene Expression | 6 | 2016 | 1589 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 492 | 0.090 |
Why?
|
| Dasatinib | 2 | 2023 | 42 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 254 | 0.090 |
Why?
|
| Tamoxifen | 1 | 2012 | 363 | 0.090 |
Why?
|
| Regeneration | 1 | 2013 | 202 | 0.090 |
Why?
|
| Ectodermal Dysplasia | 1 | 2010 | 43 | 0.090 |
Why?
|
| Acute Disease | 3 | 2019 | 1088 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 519 | 0.090 |
Why?
|
| Neonatal Screening | 1 | 2012 | 179 | 0.090 |
Why?
|
| Segmental Duplications, Genomic | 1 | 2010 | 81 | 0.090 |
Why?
|
| Confidence Intervals | 2 | 2021 | 274 | 0.090 |
Why?
|
| Ganglioneuroblastoma | 1 | 2009 | 5 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 646 | 0.080 |
Why?
|
| Apolipoprotein E4 | 1 | 2009 | 42 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2009 | 53 | 0.080 |
Why?
|
| Limb Deformities, Congenital | 1 | 2010 | 104 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2024 | 5960 | 0.080 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 374 | 0.080 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2007 | 445 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 201 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2014 | 794 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2021 | 1396 | 0.080 |
Why?
|
| Software | 2 | 2018 | 669 | 0.080 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2009 | 118 | 0.080 |
Why?
|
| Family | 2 | 2010 | 561 | 0.080 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2018 | 25 | 0.080 |
Why?
|
| Luciferases | 2 | 2019 | 137 | 0.080 |
Why?
|
| Arabinonucleosides | 2 | 2020 | 32 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1021 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 611 | 0.080 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 284 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2015 | 1105 | 0.070 |
Why?
|
| Clinical Trials as Topic | 3 | 2019 | 1078 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2021 | 1365 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2013 | 511 | 0.070 |
Why?
|
| Autistic Disorder | 1 | 2011 | 345 | 0.070 |
Why?
|
| Genetic Linkage | 4 | 2015 | 449 | 0.070 |
Why?
|
| Connexins | 1 | 2007 | 56 | 0.070 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2017 | 4 | 0.070 |
Why?
|
| APOBEC-1 Deaminase | 1 | 2017 | 12 | 0.070 |
Why?
|
| X-linked Nuclear Protein | 2 | 2018 | 16 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 994 | 0.070 |
Why?
|
| Pregnancy | 1 | 2020 | 7045 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2010 | 416 | 0.070 |
Why?
|
| Caspase 8 | 1 | 2017 | 22 | 0.070 |
Why?
|
| Receptor, ErbB-3 | 1 | 2017 | 16 | 0.070 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 105 | 0.070 |
Why?
|
| Loss of Function Mutation | 1 | 2018 | 141 | 0.070 |
Why?
|
| Keratins | 1 | 2017 | 55 | 0.070 |
Why?
|
| HLA-A Antigens | 1 | 2017 | 35 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 1165 | 0.070 |
Why?
|
| Human papillomavirus 16 | 1 | 2017 | 39 | 0.070 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2017 | 64 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2017 | 83 | 0.070 |
Why?
|
| RNA Splicing | 1 | 2018 | 223 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2007 | 397 | 0.070 |
Why?
|
| Genotyping Techniques | 2 | 2019 | 99 | 0.070 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 109 | 0.070 |
Why?
|
| Sequence Tagged Sites | 2 | 1996 | 27 | 0.070 |
Why?
|
| Hearing Loss | 1 | 2007 | 129 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 263 | 0.060 |
Why?
|
| Societies, Medical | 3 | 2018 | 676 | 0.060 |
Why?
|
| Information Dissemination | 2 | 2018 | 186 | 0.060 |
Why?
|
| Humerus | 1 | 2005 | 14 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2024 | 3289 | 0.060 |
Why?
|
| Protein Binding | 2 | 2022 | 1736 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2018 | 83 | 0.060 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 134 | 0.060 |
Why?
|
| Muscle Hypotonia | 2 | 2019 | 186 | 0.060 |
Why?
|
| Spinal Cord Compression | 1 | 2024 | 30 | 0.060 |
Why?
|
| Chromosome Breakpoints | 2 | 2014 | 80 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2024 | 59 | 0.060 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2024 | 68 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 1073 | 0.060 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2003 | 19 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 4 | 2011 | 1590 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2005 | 146 | 0.060 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 4306 | 0.060 |
Why?
|
| Imatinib Mesylate | 1 | 2023 | 45 | 0.050 |
Why?
|
| Linkage Disequilibrium | 2 | 2015 | 305 | 0.050 |
Why?
|
| Brain Injuries | 1 | 2009 | 760 | 0.050 |
Why?
|
| Neck | 1 | 2024 | 134 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2023 | 112 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2018 | 1155 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2018 | 655 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2015 | 658 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2022 | 35 | 0.050 |
Why?
|
| Wiskott-Aldrich Syndrome | 2 | 2000 | 22 | 0.050 |
Why?
|
| Heterozygote | 2 | 2019 | 679 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2024 | 377 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 6168 | 0.050 |
Why?
|
| STAT Transcription Factors | 1 | 2022 | 23 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2022 | 91 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 2 | 2013 | 270 | 0.050 |
Why?
|
| Heart Defects, Congenital | 2 | 2010 | 1778 | 0.050 |
Why?
|
| Ukraine | 1 | 2021 | 15 | 0.050 |
Why?
|
| Cell Line | 3 | 2018 | 2787 | 0.050 |
Why?
|
| Laboratories | 1 | 2022 | 83 | 0.050 |
Why?
|
| Breast | 1 | 2022 | 214 | 0.050 |
Why?
|
| Melphalan | 1 | 2021 | 49 | 0.050 |
Why?
|
| Busulfan | 1 | 2021 | 44 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2021 | 131 | 0.050 |
Why?
|
| Calcineurin | 1 | 2001 | 100 | 0.050 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2020 | 44 | 0.040 |
Why?
|
| Nervous System | 1 | 2001 | 128 | 0.040 |
Why?
|
| Uganda | 1 | 2020 | 69 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 300 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 2074 | 0.040 |
Why?
|
| Muscle, Skeletal | 3 | 2011 | 928 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2021 | 245 | 0.040 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2000 | 56 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 657 | 0.040 |
Why?
|
| Genes, p16 | 1 | 2019 | 13 | 0.040 |
Why?
|
| Organ Specificity | 2 | 2018 | 427 | 0.040 |
Why?
|
| Heredity | 1 | 2019 | 13 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 4385 | 0.040 |
Why?
|
| Speech-Language Pathology | 1 | 2019 | 13 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2001 | 223 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1685 | 0.040 |
Why?
|
| Mucositis | 1 | 2019 | 17 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2022 | 322 | 0.040 |
Why?
|
| Cytidine Deaminase | 1 | 2019 | 31 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 5 | 1 | 2018 | 1 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2000 | 171 | 0.040 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2018 | 40 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2019 | 79 | 0.040 |
Why?
|
| X Chromosome | 1 | 2000 | 339 | 0.040 |
Why?
|
| Codon, Nonsense | 1 | 2019 | 129 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2019 | 173 | 0.040 |
Why?
|
| Seminoma | 1 | 2018 | 8 | 0.040 |
Why?
|
| Drosophila | 2 | 2001 | 766 | 0.040 |
Why?
|
| Disease Progression | 2 | 2015 | 1984 | 0.040 |
Why?
|
| Smad Proteins | 1 | 2018 | 43 | 0.040 |
Why?
|
| Snail Family Transcription Factors | 1 | 2018 | 24 | 0.040 |
Why?
|
| Dactinomycin | 1 | 2018 | 68 | 0.040 |
Why?
|
| Entropy | 1 | 2018 | 26 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2018 | 53 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 300 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 217 | 0.040 |
Why?
|
| Protein Biosynthesis | 2 | 1999 | 668 | 0.040 |
Why?
|
| Guanosine | 1 | 2018 | 11 | 0.040 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2018 | 20 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 745 | 0.040 |
Why?
|
| Centromere | 1 | 2018 | 107 | 0.040 |
Why?
|
| Etoposide | 1 | 2018 | 119 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 67 | 0.040 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2000 | 201 | 0.040 |
Why?
|
| IMP Dehydrogenase | 1 | 2018 | 21 | 0.040 |
Why?
|
| Eukaryotic Initiation Factor-1 | 1 | 2017 | 4 | 0.040 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2017 | 8 | 0.040 |
Why?
|
| Monosomy | 1 | 2017 | 24 | 0.040 |
Why?
|
| DNA Primers | 2 | 1995 | 668 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 728 | 0.040 |
Why?
|
| Brazil | 1 | 2017 | 122 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 67 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3441 | 0.040 |
Why?
|
| Purines | 1 | 2018 | 107 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2017 | 21 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 139 | 0.040 |
Why?
|
| Cloning, Molecular | 2 | 1996 | 900 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 507 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2009 | 142 | 0.040 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2017 | 21 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 372 | 0.040 |
Why?
|
| Glaucoma | 1 | 1998 | 89 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 266 | 0.040 |
Why?
|
| Pol1 Transcription Initiation Complex Proteins | 1 | 2017 | 5 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2018 | 238 | 0.040 |
Why?
|
| Gain of Function Mutation | 1 | 2018 | 104 | 0.040 |
Why?
|
| Insulin | 1 | 2022 | 1189 | 0.040 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 41 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2018 | 201 | 0.040 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 93 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 64 | 0.030 |
Why?
|
| Curriculum | 1 | 2022 | 715 | 0.030 |
Why?
|
| MEF2 Transcription Factors | 1 | 2016 | 33 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 243 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2016 | 92 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2018 | 307 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 74 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 173 | 0.030 |
Why?
|
| Minisatellite Repeats | 1 | 1996 | 43 | 0.030 |
Why?
|
| Calcium | 1 | 2001 | 1096 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2017 | 135 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 420 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2015 | 30 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2015 | 49 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2015 | 14 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2015 | 20 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 650 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2017 | 399 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2017 | 835 | 0.030 |
Why?
|
| Chromosome Banding | 2 | 2010 | 141 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 511 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1995 | 73 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 81 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 1294 | 0.030 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2015 | 40 | 0.030 |
Why?
|
| CREB-Binding Protein | 1 | 2015 | 63 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 98 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2015 | 106 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1725 | 0.030 |
Why?
|
| DNA Damage | 1 | 2018 | 517 | 0.030 |
Why?
|
| Clone Cells | 1 | 2015 | 167 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2015 | 317 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 133 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2014 | 142 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2015 | 147 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 164 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 157 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2016 | 222 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 149 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 190 | 0.030 |
Why?
|
| Telomere | 1 | 2016 | 205 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2015 | 128 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2014 | 29 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 2015 | 179 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2014 | 29 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 2962 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 142 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 66 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 183 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 572 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 309 | 0.030 |
Why?
|
| Maxillofacial Abnormalities | 1 | 2013 | 6 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1995 | 226 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 750 | 0.030 |
Why?
|
| Paternity | 1 | 2013 | 8 | 0.030 |
Why?
|
| Forensic Genetics | 1 | 2013 | 10 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2016 | 391 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 421 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2014 | 158 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 1437 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 31 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 212 | 0.030 |
Why?
|
| Ohio | 1 | 2013 | 88 | 0.030 |
Why?
|
| Consanguinity | 1 | 2013 | 107 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1703 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 2926 | 0.030 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 124 | 0.030 |
Why?
|
| Myoblasts | 1 | 2013 | 30 | 0.030 |
Why?
|
| Haploidy | 1 | 2013 | 19 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 211 | 0.030 |
Why?
|
| Stem Cells | 1 | 2018 | 710 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 268 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 577 | 0.030 |
Why?
|
| Suppression, Genetic | 1 | 2013 | 44 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2017 | 805 | 0.030 |
Why?
|
| Hearing Disorders | 1 | 1992 | 25 | 0.030 |
Why?
|
| Facies | 1 | 2013 | 155 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 255 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2015 | 1069 | 0.020 |
Why?
|
| Zebrafish Proteins | 1 | 2013 | 105 | 0.020 |
Why?
|
| Histones | 1 | 2015 | 528 | 0.020 |
Why?
|
| Research Report | 1 | 2012 | 69 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 322 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 381 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 838 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2013 | 410 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2015 | 322 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 1616 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 429 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 254 | 0.020 |
Why?
|
| Physical Chromosome Mapping | 1 | 2010 | 56 | 0.020 |
Why?
|
| Point Mutation | 1 | 2012 | 345 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2018 | 3777 | 0.020 |
Why?
|
| Carrier State | 1 | 2011 | 76 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2010 | 12 | 0.020 |
Why?
|
| Dysferlin | 1 | 2010 | 3 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2013 | 579 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 230 | 0.020 |
Why?
|
| Zebrafish | 1 | 2013 | 380 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 513 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 239 | 0.020 |
Why?
|
| Smoking | 1 | 2015 | 1018 | 0.020 |
Why?
|
| Amyloid | 1 | 2010 | 64 | 0.020 |
Why?
|
| Multigene Family | 1 | 2011 | 298 | 0.020 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 2 | 2000 | 10 | 0.020 |
Why?
|
| Dependovirus | 1 | 2010 | 125 | 0.020 |
Why?
|
| Unconsciousness | 1 | 2009 | 17 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 1995 | 709 | 0.020 |
Why?
|
| Leg | 1 | 2010 | 154 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 446 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 326 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2009 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2009 | 200 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2010 | 122 | 0.020 |
Why?
|
| Observer Variation | 1 | 2009 | 297 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 1999 | 70 | 0.020 |
Why?
|
| Executive Function | 1 | 2009 | 103 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2014 | 799 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 1343 | 0.020 |
Why?
|
| Research Personnel | 1 | 2009 | 117 | 0.020 |
Why?
|
| Monocytes | 1 | 2010 | 343 | 0.020 |
Why?
|
| Craniofacial Abnormalities | 1 | 2010 | 243 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1868 | 0.020 |
Why?
|
| Connexin 30 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Connexin 26 | 1 | 2007 | 13 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 2007 | 85 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2010 | 973 | 0.020 |
Why?
|
| Brain Concussion | 1 | 2009 | 225 | 0.020 |
Why?
|
| Canada | 1 | 2007 | 292 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2010 | 706 | 0.020 |
Why?
|
| Sequence Alignment | 2 | 1998 | 623 | 0.020 |
Why?
|
| Apoptosis | 1 | 2010 | 1791 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2011 | 818 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1272 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 181 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 2809 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 2792 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 3601 | 0.010 |
Why?
|
| Heteroduplex Analysis | 1 | 1999 | 4 | 0.010 |
Why?
|
| Codon, Terminator | 1 | 1999 | 26 | 0.010 |
Why?
|
| Hydro-Lyases | 1 | 1998 | 9 | 0.010 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 1997 | 41 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1999 | 228 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1996 | 81 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 411 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 1995 | 76 | 0.010 |
Why?
|
| RNA | 1 | 1999 | 577 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 472 | 0.010 |
Why?
|
| Hedgehog Proteins | 1 | 1995 | 192 | 0.010 |
Why?
|
| Waardenburg Syndrome | 1 | 1992 | 11 | 0.010 |
Why?
|
| Fetus | 1 | 1995 | 575 | 0.010 |
Why?
|